{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:53:56Z","timestamp":1790070836662,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.neurol.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T09:00:20Z","timestamp":1583830820000},"page":"677-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-2413","authenticated-orcid":false,"given":"M.","family":"Lilamand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hourregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurol.2019.12.006_bib0265","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9064","key":"10.1016\/j.neurol.2019.12.006_bib0270","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(96)10203-8","article-title":"Auguste D and Alzheimer's disease","volume":"349","author":"Maurer","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2019.12.006_bib0275","series-title":"The Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1980"},{"issue":"7","key":"10.1016\/j.neurol.2019.12.006_bib0280","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2019.12.006_bib0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0290","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0295","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.neurol.2019.12.006_bib0300","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.neurol.2019.12.006_bib0305","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0315","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","article-title":"Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia","volume":"13","author":"Simonsen","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.neurol.2019.12.006_bib0320","doi-asserted-by":"crossref","first-page":"e-1-16","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.07.001","article-title":"Plasma amyloid-\u03b2 and risk of Alzheimer's disease in the Framingham Heart Study","volume":"11","author":"Chouraki","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.neurol.2019.12.006_bib0330","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"10.1016\/j.neurol.2019.12.006_bib0335","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurol.2019.12.006_bib0340","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","article-title":"Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies","volume":"88","author":"Lai","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"s1","key":"10.1016\/j.neurol.2019.12.006_bib0345","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.3233\/JAD-179926","article-title":"From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer's disease","volume":"64","author":"Zetterberg","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.neurol.2019.12.006_bib0350","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study","volume":"12","author":"Duits","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2019.12.006_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.06.008","article-title":"Impact of harmonization of collection tubes on Alzheimer's disease diagnosis","volume":"10","author":"Lehmann","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2019.12.006_bib0365","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1373\/clinchem.2011.178368","article-title":"Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis","volume":"58","author":"Perret-Liaudet","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.neurol.2019.12.006_bib0370","first-page":"02381","article-title":"Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting","volume":"7","author":"Dumurgier","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.neurol.2019.12.006_bib0375","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/1567205015666180110113238","article-title":"Relevance of follow-up in patients with core clinical criteria for Alzheimer disease and normal CSF biomarkers","volume":"15","author":"Vercruysse","year":"2018","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"10.1016\/j.neurol.2019.12.006_bib0380","doi-asserted-by":"crossref","first-page":"e026380","DOI":"10.1136\/bmjopen-2018-026380","article-title":"What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France","volume":"9","author":"Cognat","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2019.12.006_bib0385","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-016-0192-z","article-title":"Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study","volume":"8","author":"Paquet","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2019.12.006_bib0390","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0395","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2019.12.006_bib0400","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archneurol.2009.55","article-title":"Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type","volume":"66","author":"Snider","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2019.12.006_bib0405","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.neurobiolaging.2007.02.016","article-title":"Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia","volume":"29","author":"Engelborghs","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2019.12.006_bib0410","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/alzrt267","article-title":"A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles","volume":"6","author":"Lehmann","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2019.12.006_bib0415","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","article-title":"Cerebrospinal fluid amyloid-42\/40 ratio in clinical setting of memory centers: a multicentric study","volume":"7","author":"Dumurgier","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2019.12.006_bib0420","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fnagi.2018.00138","article-title":"Relevance of A\u03b242\/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale","volume":"10","author":"Lehmann","year":"2018","journal-title":"Front Aging Neurosci"},{"issue":"Pt\u00a011","key":"10.1016\/j.neurol.2019.12.006_bib0425","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2019.12.006_bib0430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jnnp.71.3.401","article-title":"Highlyincreased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?","volume":"71","author":"Kapaki","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0435","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3233\/JAD-151111","article-title":"Differential diagnosis of dementia with high levels of cerebrospinal fluid tau protein","volume":"51","author":"Grangeon","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","article-title":"Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment","volume":"13","author":"Herukka","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.neurol.2019.12.006_bib0450","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3233\/JAD-132672","article-title":"Whoneeds cerebrospinal biomarkers? A national survey in clinical practice","volume":"40","author":"Troussi\u00e8re","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"Pt\u00a05","key":"10.1016\/j.neurol.2019.12.006_bib0455","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","article-title":"Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage","volume":"138","author":"Vos","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2019.12.006_bib0460","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2019.12.006_bib0465","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00415-013-7160-3","article-title":"Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study","volume":"261","author":"Mouton-Liger","year":"2014","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2019.12.006_bib0470","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3233\/JAD-170511","article-title":"Alzheimer's disease biomarkers and future decline in cognitive normal older adults","volume":"60","author":"Dumurgier","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.neurol.2019.12.006_bib0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jnnp.2006.100529","article-title":"Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women","volume":"78","author":"Gustafson","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0480","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000068478","article-title":"Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds","volume":"15","author":"Skoog","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"10.1016\/j.neurol.2019.12.006_bib0485","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.25071","article-title":"Age, vascular health, and Alzheimer disease biomarkers in an elderly sample","volume":"82","author":"Vemuri","year":"2017","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2019.12.006_bib0490","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","article-title":"Neuropathology of cognitively normal elderly","volume":"62","author":"Knopman","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"issue":"19","key":"10.1016\/j.neurol.2019.12.006_bib0495","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neurol.2019.12.006_bib0500","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/01.wnl.0000191298.68045.50","article-title":"Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease","volume":"66","author":"Prohovnik","year":"2006","journal-title":"Neurology"},{"issue":"10\u201311","key":"10.1016\/j.neurol.2019.12.006_bib0505","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0531-5565(02)00141-9","article-title":"Tau aggregation in the hippocampal formation: an ageing or a pathological process?","volume":"37","author":"Delacourte","year":"2002","journal-title":"Exp Gerontol"},{"issue":"3","key":"10.1016\/j.neurol.2019.12.006_bib0515","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2017.11","article-title":"Alzheimer disease: CSF biomarkers for Alzheimer disease\u00a0\u2014\u00a0approaching consensus","volume":"13","author":"Galasko","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2019.12.006_bib0520","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1532-5415.2007.01600.x","article-title":"Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment","volume":"56","author":"Carpenter","year":"2008","journal-title":"J Am Geriatr Soc"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720303891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720303891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:40:56Z","timestamp":1758519656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720303891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0035378720303891"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2019.12.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}